darunavir + TMC41629

**Darunavir + TMC41629** is a non-approved combination of the HIV-1 protease inhibitor darunavir and TMC41629, an investigational small molecule pharmacokinetic booster. Darunavir is a well-established antiretroviral that inhibits the HIV-1 protease enzyme, preventing viral replication and maturation[2][3][5]. TMC41629 is a booster, distinct from ritonavir or cobicistat, developed to increase the systemic exposure of darunavir by inhibiting metabolic enzymes and/or transporters responsible for darunavir's clearance[1]. Co-administration of TMC41629 with darunavir results in increased darunavir plasma concentrations in preclinical models, with the aim to improve efficacy and possibly tolerability or patient convenience compared to current boosting agents[1]. This combination is primarily studied in the context of HIV-1 infection, and clinical development status is not clearly established.

Brand names

Prezista (darunavir only; no fixed-dose approved combination with TMC41629)None for the combination

Other names

darunavir + TMC41629